# Vaccine Effectiveness against Referral to Hospital and Severe Lung Injury Associated with COVID-19: A Population-based Case-control Study in St. Petersburg, Russia

Anton Barchuk<sup>1,6,7⊠</sup>, Mikhail Cherkashin<sup>2</sup>, Anna Bulina<sup>1</sup>, Natalia Berezina<sup>2</sup>, Tatyana Rakova<sup>2</sup>, Darya Kuplevatskaya<sup>2</sup>, Oksana Stanevich<sup>3,4</sup>, Dmitriy Skougarevskiy<sup>1</sup>, and Artemy Okhotin<sup>5</sup>

<sup>1</sup>European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
 <sup>2</sup>Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
 <sup>3</sup>First Pavlov State Medical University of St. Petersburg, Ulitsa L'va Tolstogo 6-8, St. Petersburg, Russia, 197022
 <sup>4</sup>Smorodintsev Research Institute of Influenza, Ulitsa Professora Popova 15/17, St. Petersburg, Russia, 197022
 <sup>5</sup>Tarusa Hospital, Karla Libknekhta Ulitsa 16, Tarusa, Russia, 249100

<sup>6</sup>Petrov National Research Medical Centre of Oncology, Pesochny, Leningradskaya Ulitsa 68, St. Petersburg, Russia, 197758

<sup>7</sup>Health Sciences, Faculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, Tampere, Finland, 33520

**Background**: Results of a randomised trial showed the safety and efficacy of Gam-COVID-Vac against COVID-19. However, compared to other vaccines used across the globe, the real-world data on the effectiveness of Gam-COVID-Vac, especially against the disease caused by Delta variant of concern, was not available. We aimed to assess the effectiveness of vaccination mainly conducted with Gam-COVID-Vac in St. Petersburg, Russia.

Methods: We designed a case-control study to assess the vaccine effectiveness (VE) against lung injury and referral to hospital. Self-reported vaccination status was collected for individuals with confirmed SARS-CoV-2 infection who were referred for initial low-dose computed tomography triage in two outpatient centres in July 3 – August 9, 2021 in St. Petersburg, Russia. We used logistic regression models to estimate the adjusted (for age, sex, and triage centre) VE for complete (>14 days after the second dose) and partial vaccination (>14 days after the first dose). We estimated the VE against referral for hospital admission, COVID-19-related lung injury assessed with LDCT, and decline in oxygen saturation.

Results: In the final analysis, 13,894 patients were included, 1,291 (9.3%) of patients met our criteria for complete vaccination status, and 495 (3.6%) were referred to hospital. In the primary analysis, the adjusted VE against referral to hospital was 81% (95% CI: 68–88) for complete vaccination. The effect of the partial vaccination was not statistically significant. The VE against referral to hospital was more pronounced in women (84%, 95% CI: 66–92) compared to men (76%, 95% CI: 51–88). Vaccine protective effect increased with increasing lung injury categories, from 54% (95% CI: 48–60) against any sign of lung injury to 76% (95% CI: 59–86) against more than 50% lung involvement. A sharp increase was observed in the probability of hospital admission with age for non-vaccinated patients in relation to an almost flat relationship for the completely vaccinated group.

**Conclusions**: COVID-19 vaccination was effective against referral to hospital in patients with symptomatic SARS-CoV-2 infection in St. Petersburg, Russia. This protection is probably mediated through VE against lung injury associated with COVID-19.

Keywords: COVID-19; vaccine effectiveness; case-control study; COVID-19 pneumonia

Correspondence: abarchuk@eu.spb.ru

### Introduction

Vaccination proved to be an effective pharmaceutical control measure during the COVID-19 pandemic. More than 4 billion doses have been already administered, but real-world evidence is not equally available for all vaccines used globally. Even NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

though the results from clinical trials of Gam-COVID-Vac [1, 2] suggested safety and efficacy similar to other COVID-19 vaccines used in population-based programmes across the globe [3, 4], this finding was met with scepticism and criticism [5–9]. Despite adoption of Gam-COVID-Vac in 49 countries, the independent safety data for this vaccine is available only from San Marino and Argentina [10, 11]. Further lacking is real-world evidence on Gam-COVID-Vac vaccine effectiveness (VE) from population-based studies.

A case-control study design and its modifications are the core methods to assess the effectiveness of vaccination in real-world settings [12]. Multiple case-control studies of COVID-19 vaccines have been published [13, 14]. The study that explored the VE of vaccines available in Scotland showed diminished protection against Delta VOC infection and hospital admission [15]. The COVID-19 pandemic in Russia has claimed more than 500,000 excess deaths by the spring of 2021 [16] while the lack of real-world evidence on the VE became a public health issue in Russia. Vaccination uptake in the country was undermined by vaccine hesitancy [17], partly driven by the lack of independent research exploring vaccine safety and effectiveness and failures to communicate the balance of benefits and harms of COVID-19 vaccination.

St. Petersburg is the second most populated city in Russia and the fourth in Europe. More than 45% of the population have contracted the SARS-CoV-2 infection by the end of April, 2021. However, only 10% received at least one dose of any vaccine by April, 2021 which is below the levels seen in other countries [18]. Low uptake by the spring of 2021 failed to stop the spread of the new Delta VOC in May–June 2021 in St. Petersburg. The spread of the Delta VOC, in turn, caused the rise in vaccination demand in the summer of 2021. As reported by the city government, by July 27, 2021, approximately 27% of the adult population of St. Petersburg received at least one dose of any vaccine, and 19% received two doses. This increase in the vaccination uptake, consequently, has led to an increase in the absolute number of vaccinated individuals who reported to have a breakthrough infection or hospital admission. Such anecdotal evidence has caused further mistrust in the vaccination programme in absence of reliable scientific reports.

In this paper we present the first independent assessment of the VE in Russia. We designed a case-control study to assess the VE against referral to hospital and lung injury in the individuals who reported symptoms and were referred for initial computed tomography assessment in two outpatient centres in St. Petersburg, Russia.

### **Methods**

### Population and study design

St. Petersburg and other cities in Russia have established a triage service for symptomatic patients with COVID-19. Symptomatic patients with confirmed SARS-CoV-2 (using polymerase chain reaction (PCR) test) are referred to outpatient triage, including brief physical examination and low-dose computed tomography (LDCT). The decision about hospital admission is based on symptoms, i.e. shortness of breath, hypoxia, overall clinical condition, and lung injury assessed with LDCT. We designed a population-based case-control study to determine the VE against hospital referral and COVID-19 lung injury in symptomatic patients with confirmed SARS-CoV-2 infection, who were referred to the LDCT triage.

We retrospectively collected individual-level patient data from two outpatient triage centres of the Medical Institute named after Berezin Sergey (MIBS), a private medical facility contracted by the city government to provide triage service for nearly half of the city districts. All patients referred to LDCT triage underwent brief physical examination, including pulse oximetry. A local computed tomography score (CT-score) was implemented in Russia [19]. It has five gradations (0, 1, 2, 3, 4) which are related to the volume of involved lung segments (0, < 25%, 25–50%, 50–75%, 75–100%). It is used in the country to define the severity of COVID-19 lung injury and to triage patients. CT-score of 3 and 4 means more than 50% of lung volume involvement and is often used as an indication for the hospital admission. Patients with CT-score less than 3, i.e. less than 50% lung injury seen on the LDCT, and in the absence of severe symptoms, are normally sent to out-patient treatment or follow-up.

### Vaccination status and outcomes

In our primary analysis, cases were all patients referred to hospital after triage starting from July 3, 2021 till August 9, 2021. Controls were the patients referred to outpatient treatment and follow-up after the LDCT triage in the same period. The information about self-reported vaccination status was collected at the time of appointment to the LDCT. The patients reported the number of doses and the dates of vaccination, the type of vaccine data was not collected. The majority of vaccinated residents in St. Petersburg received Gam-COVID-Vac with marginal proportions for two other vaccines (mostly due to limited supply).

We used several definitions of the vaccination status. Complete vaccination status was assigned to the patients who had reported receiving two doses at least 14 days before the referral to the LDCT triage. Partial vaccination status was assigned to the patients who failed to meet the above criteria for complete vaccination, but had reported receiving one dose at least 14 days prior to the referral. In the secondary analyses, we used the CT-score [19] and oxygen saturation as the secondary outcomes to assess the VE against COVID-19 lung injury. Oxygen saturation was grouped in the ranges according to the NEWS2 score [20] which was well-validated in non-COVID-19 settings. It has four gradations (0, 1, 2, 3) which are related to the oxygen saturation in the following categories: >95, 94–95, 92–93, <92.

### Statistical analysis

We modeled our study plan following the WHO interim guidance to evaluate COVID-19 vaccine effectiveness [21]. We collected information on all patients referred to the LDCT triage, as most patients were sent for out-patient treatment and outpatient follow-up. We used unconditional logistic regression for our primary and secondary outcomes to estimate odds ratios (ORs) for vaccination status among cases and controls, which approximates ORs for the outcomes (hospital admission, different levels of lung injury and decline in oxygen saturation) among the vaccinated and non-vaccinated patients. The VE was calculated as  $100\% \times (1-OR)$  adjusted for age (continuous variable), sex, and the triage LDCT centre. Our sample size of 495 hospitalized patients (cases), 13,399 non-hospitalized patients (controls), and 1,291 patients with the complete vaccination status (exposure level of 9.3%) provides 80% power to detect an odds ratio of 0.58 (or the VE of 42%) and 1.46 (or the VE of -46%) for hospitalization at the 5% alpha level in our unmatched case-control study. All standard errors and confidence intervals were adjusted for heteroskedasticity with the Huber-Eicker-White sandwich estimator.

In the sensitivity analysis, for the complete vaccination status, we stratified the period after second dose to the period of 14 to 55 days and the period of 56 or more days. Finally, we investigated the relationship between the hospitalization and the thin plate regression spline of the patient age by vaccination status in a semiparametric logistic regression.

### **Ethical considerations**

The Ethics Committee of the MIBS approved the study on June 21, 2020. The Ethics Committee of the Pavlov First Saint Petersburg State Medical University approved the joint study of COVID-19 vaccine effectiveness in St. Petersburg on July 15, 2020. All research was performed following the relevant guidelines and regulations. All participants signed the informed consent upon referral to the LDCT triage. The joint study of COVID-19 vaccine effectiveness in St. Petersburg was registered at ClinicalTrials.gov (NCT04981405, date of registration — Aug 4, 2021). This publication covers the data collected at the two outpatient centres of the MIBS that contributed to the study data.

### Contribution and role of the funding source

The study team was entirely responsible for the study design and for collecting and analysing the data. There was no additional funding of the study provided.

## Results

Overall, 13,894 patients were included in the final analysis. Patients characteristics are presented in Table 1. Among all patients, 1,965 (14.1%) received at least one dose, 1,379 (9.9%) received two doses, 1,291 (9.3%) met our criteria for complete vaccination status, and additionally 449 (3.2%) met our criteria for partial vaccination status. 495 (3.6%) patients were referred to hospital after the LDCT triage. The majority of referred patients (63.1%) had CT-score 3–4, or >50% lung involvement on LDCT. Patients referred to hospital were also older (66.1% were older than 60 years). Only 17 (3.4%) patients who were referred for hospital admission met the criteria for complete vaccination.

In the primary analysis, the adjusted VE against referral to hospital admission was 81% (95% CI: 68–88) for complete vaccination (Table 2). The effect of the partial vaccination against referral to hospital was 35% (95% CI: -21–65).

Crude and adjusted ORs and VE against lung injury following the LDCT assessment and decline in oxygen saturation is presented in Table 2. Only a few patients had more than 75% of lung involvement and none in the vaccination group, so we calculated the VE for the combined category, which included patients with more than 50% of lung involvement. The VE increased with the lung injury categories, from 54% (95% CI:48–60) against any signs of lung injury to 76% (95% CI:59–86) against more than 50% lung injury. The VE against different levels of hypoxia was consistent (Table 2).

The VE against hospital admission was more pronounced in women (84%, 95% CI: 66–92) compared to men (76%, 95% CI: 51–88) and older age groups (77%, 95% CI: 62–86) (Table 3). We observed a sharp increase in the probability of hospital admission with age for non-vaccinated patients in relation to an almost flat relationship between age and the probability of hospital admission for the completely vaccinated group of patients (Figure 1). There was no difference in the VE by the LDCT triage centre. Crude VE estimates were lower compared to the adjusted VE. The adjusted VE by the time elapsed from the second dose was 60% (95% CI: 5–83) for the 14–55 day period and 85% (95% CI: 72–92) for the 56+ day period.

**Table 1.** Characteristics of Persons with Covid-19 referred to the LDCT Triage.

		Overall	Referred to outpatient follow-up (%)	Referred to hospital (%)
		13,894	13,399	495
Age (mean (SD))		48.2 (15.9)	47.6 (15.6)	64.9 (14.6)
Age (categories (%))				
	18-30	2,050 (14.8)	2,042 (15.2)	8 (1.6)
	31-40	2,961 (21.3)	2,931 (21.9)	30 (6.1)
	41-50	2,746 (19.8)	2,698 (20.1)	48 (9.7)
	51-60	2,750 (19.8)	2,668 (19.9)	82 (16.6)
	60+	3,387 (24.4)	3,060 (22.8)	327 (66.1)
Sex (%)				
	Female	8,585 (61.8)	8,270 (61.7)	315 (63.6)
	Male	5,309 (38.2)	5,129 (38.3)	180 (36.4)
Triage centre (%)				
	1	5,656 (40.7)	5,424 (40.5)	232 (46.9)
	2	8,238 (59.3)	7,975 (59.5)	263 (53.1)
Vaccine doses reported (%)				
	None	11,929 (85.9)	11,464 (85.6)	465 (93.9)
	1 dose	586 (4.2)	573 (4.3)	13 (2.6)
	2 doses	1,379 (9.9)	1,362 (10.2)	17 (3.4)
Vaccination status (%)				
	Non-vaccinated	12,154 (87.5)	11,687 (87.2)	467 (94.3)
	Partial vaccination	449 (3.2)	438 (3.3)	11 (2.2)
	Complete vaccination	1,291 (9.3)	1,274 (9.5)	17 (3.4)
Oxygen saturation (median [IQR])	1	97 [97, 98]	97 [97, 98]	94 [92, 96]
Oxygen saturation (%)		. , ,	. , ,	
,	96% and more	13,509 (97.5)	13,349 (99.9)	160 (32.5)
	94–95%	152 (1.1)	9 (0.1)	143 (28.9)
	92-93%	140 (1.0)	1 (0.0)	139 (28.1)
	Less than 92%	53 (0.4)	2 (0.0)	51 (10.3)
	Missing data	40 (0.3)	38 (0.3)	2 (0.4)
Lung injury (%)	J	( )	,	,
	No injury	4,526 (32.6)	4,526 (33.8)	0 (0.0)
	<25%	7,638 (55.0)	7,638 (57.0)	0 (0.0)
	25-50%	1,415 (10.2)	1,232 (9.2)	183 (37.0)
	50-75%	284 (2.0)	3 (0.0)	281 (56.8)
	>75%	31 (0.2)	0 (0.0)	31 (6.3)

Table 2. Effectiveness of Complete Vaccination Against Referral to Hospital, Lung Injury, and Hypoxia.

		Crude OR (95% CI)	Crude VE (95% CI)	Adjusted OR (95% CI)	Adjusted VE (95% CI)
Triage result					
_	Outpatient follow-up	1.00	_	1.00	_
	Referral to hospital	0.34 (0.21-0.55)	66% (45–79)	0.19 (0.12-0.32)	81% (68–88)
Lung injury	-				
	No signs of lung injury	1.00	_	1.00	_
	Any signs of lung injury	0.64 (0.57-0.72)	36% (28–43)	0.46 (0.40-0.52)	54% (48–60)
	More than 25%	0.60 (0.48-0.72)	41% (28–52)	0.36 (0.29-0.45)	64% (55–71)
	More than 50%	0.42 (0.26–0.69)	58% (31–74)	0.24 (0.14-0.41)	76% (59–86)
Oxygen saturation					
, ,	96% and more	1.0	_	1.0	_
	Less than 96%	0.47 (0.28-0.78)	53% (22–72)	0.30 (0.18-0.51)	70% (49–82)
	Less than 94%	0.58 (0.32–1.07)	42% (-7–68)	0.39 (0.21–0.72)	61% (28–79)
	Less than 92%	0.58 (0.18–1.85)	42% (-85–82)	0.34 (0.10–1.12)	66% (-12–90)

Table 3. Effectiveness of Complete Vaccination Against Referral to Hospital, According to Age Group, Sex, and Triage Centre.

		Crude OR (95% CI)	Crude VE (95% CI)	Adjusted OR (95% CI)	Adjusted VE (95% CI)
Sex					
	Female	0.26 (0.13-0.53)	74% (47–87)	0.16 (0.08-0.34)	84% (66–92)
	Male	0.46 (0.24-0.91)	54% (9–76)	0.24 (0.12-0.49)	76% (51–88)
Age					
	18-49	0.43 (0.10-1.74)	57% (-74–90)	0.37 (0.09–1.50)	63% (-51–91)
	50 and older	0.23 (0.13-0.38)	77% (62–87)	0.18 (0.11–0.31)	82% (69–89)
Triage centre					
	1	0.34 (0.16-0.72)	66% (28–84)	0.21 (0.10-0.46)	79% (54–90)
	2	0.35 (0.18-0.65)	65% (35–82)	0.18 (0.09-0.36)	82% (64–91)




Figure 1. Probability of Referral to Hospital, According to Age and Vaccination Status (Shaded Areas Are 95% CI).

# **Discussion**

This is the first study examining the real-world effectiveness of COVID-19 vaccination in Russia, and one of the first studies globally to provide information about the vaccine protective effect against COVID-19-associated lung injury. Vaccination showed 81% protection against referral to hospital in patients with symptomatic SARS-CoV-2 infection during the third wave of COVID-19 pandemic caused by Delta VOC in St. Petersburg. It is quite similar to the VE against Delta VOC reported for other COVID-19 vaccines [15]. Previously, only in-vitro data about reduced virus-neutralizing activity of Gam-COVID-Vac was published [22], but it was not clear how laboratory findings convert into clinical practice.

The clear strength of this study is the availability of independent lung injury assessment using the LDCT. The radiologists did not have information on the vaccination status, while the computed tomography was applied as a triage method for all symptomatic patients. The protective effect of vaccination was consistent against all grades of lung injury. We did not observe 75% or more lung tissue involvement during the LDCT in the group of fully vaccinated patients, suggesting strong and consistent protective effect. Protective effect was also observed against the decline in oxygen saturation. It was clear that both secondary outcomes (lung injury and decline in oxygen saturation) are closely related, but the oxygen saturation and LDCT were independently evaluated at the triage centres. Both factors are independently influencing the decision to refer to hospital, thus explaining the greater VE against hospital admission than for CT-score and oxygen saturation alone. These results further support the findings of the primary analysis.

Since all the patients in our study had COVID-19, our results provide specific information on vaccination impact on disease severity and its clinical course. When breakthrough infections are evolving as a cause of major concern, our data is assuring that the vaccine effect is going beyond the risk of contracting the infection. It shows that vaccination significantly diminishes disease severity and protects the lungs from virus-induced injury.

While SARS-CoV-2 is likely converting from a pandemic virus to an endemic one, the role of vaccination is also evolving from pandemic control to damage control. Our data shows that it is feasible. Infection fatality rate for COVID-19 is progressively increasing with age in St. Petersburg [18]. Our data shows that it is an effective way of protecting the most vulnerable elderly persons from devastating consequences of the pandemic.

Lung injury is not only observed in COVID-19 but also in many other respiratory viral infections [23]. Lung injury leading to pneumonia and acute respiratory distress syndrome is a major cause of morbidity and mortality in these diseases. Lung imaging with computed tomography were used for assessment and risk stratification in COVID-19 [24]. However, in the United States and Europe computed tomography was discouraged by the professional societies as the primary imaging modality in mild COVID-19 due to high cost and transmission risk with emphasis placed on clinical assessment instead [25]. In Russia, due to less developed primary care and the low cost of the LDCT, it became the primary imaging modality used for COVID-19 triage. This offered the unique opportunity to assess the VE against lung injury detected with LDCT.

Our study does not provide direct evidence on the VE against SARS-CoV-2 infection and symptomatic disease. However, some indirect inferences can be made when analysing the characteristics of the overall patient group in our study. By July 27, 2021, the city government reported that at least one dose of vaccine was given to 1,178,266 residents of St. Petersburg (26.5% of

the adult population), and 819,768 received two doses (18.5% of the adult population). In our study, among 13,992 symptomatic patients who were referred to the LDCT triage, only 14.1% received at least one dose, and 9.3% received two doses. In the absence of individual-level data, we can only estimate crude effectiveness against the symptomatic disease, which is around 50%. However, the adjustment for the age and sex in the estimation of the VE against hospital admission in our study moved the point estimate from roughly 66% to 81%. It is likely that our crude indirect estimate of the VE against symptomatic disease is also underestimated. However, if we combine the protective effect against symptomatic disease and hospital admission, it is in line with the findings for other vaccines [13].

The VE against Delta VOC for one dose of vaccine was lower than for two doses, and the effect did not clearly manifest until at least 28 days after the first one [15]. We obtained similar results in our study. The point estimate for partial vaccination was 35%, but the confidence interval for the corresponding OR included unity, suggesting inadequate sample size due to the minimum detectable VE of 70% for the partial vaccination exposure as our power calculations show. It should be noted that in Russia the recommended 21-day interval between the first and the second dose of Gam-COVID-Vac is usually strictly followed. In contrast to another study [13] we did not find any possible indications of waning efficacy. The VE was higher in patients with longer period after the second dose. However, these results should be interpreted with caution, as possible biases can intervene in the stratified analysis of observational data.

There are several important limitations of our study. We did not have the information on the vaccine type, so the estimated VE represent an average effect of vaccination in St. Petersburg. However, according to official statistics, by July 27, 2021, in St. Petersburg, among 1,227,496 individuals who received at least one vaccine dose, 1,178,266 or 96% received Gam-COVID-Vac, and the rest is distributed between the other two vaccines (EpiVacCorona — 21,943 or 1.7% and KoviVac 27,287 or 2.2%). It is safe to assume that our study approximates the effectiveness of Gam-COVID-Vac. The effectiveness for EpiVacCorona and KoviVac would be difficult to derive from observational case-control studies due to negligible uptake.

Another important limitation of our study is possible referral bias. Patients were referred to the triage centres if they had positive PCR tests and disease symptoms, but the decision to refer was left at the physician's discretion. We cannot rule out that the vaccination status was influencing this decision. If this is the case, in our data we would observe more severely ill vaccinated individuals than the unvaccinated ones. Alternatively, the physicians may fully rely on vaccine protection and never refer the vaccinated patients to the triage. However, we observed a considerable number of vaccinated individuals at the triage centres. Therefore, we believe that the referral bias would result in underestimation of the VE. Vaccination could also influence patients' medical care seeking behaviour. We assume that self-assurance on vaccine protection would predominantly prevent patients with mild disease from seeking medical care, and this would also lead to underestimation of VE against severe disease in our study.

The study results may be also biased if the triage referred symptomatic patients to hospital based on their vaccination status. To the best of our knowledge, this decision was solely based on physical examination and the LDCT results. The vaccination status was collected for research purposes, was not a part of any official medical records. There is little reason to believe that the vaccine influenced the decision to refer the patient to hospital.

Finally, the data we used in our study was collected at the triage centres and not in hospitals. Even though all patients triaged for inpatient treatment were followed-up by the LDCT centre's personnel from the moment they were referred to the hospital till hospital admission, we do not know the length or the outcome of the hospital admission itself. It is also possible that the patients triaged for outpatient treatment were later admitted. Our study covers only one point in their disease course and traces only the decisions made in the triage centres.

Additional observational studies are needed to assess the vaccination effectiveness against SARS-CoV-2 infection and COVID-19 associated death. Given the limitations of our data, we were only able to estimate the protective effect against lung injury and referral to hospital. However, it is safe to assume that those outcomes pose as a surrogate for COVID-19-associated death. Our study does not provide any information on the vaccine safety, but at least for Gam-COVID-Vac, the safety data are available from independent sources [10, 11].

In conclusion, we showed that COVID-19 vaccination is effective against referral to hospital in patients with symptomatic SARS-CoV-2 infection in St. Petersburg, Russia. The protection against hospital admission is probably mediated through protection against lung injury associated with COVID-19. Real-world evidence on the VE against COVID-19 should be integrated into population-based vaccination programmes to negotiate the balance of benefits and harms of this effective COVID-19 control measure, that is likely gaining even more importance in the light of gradual ceasing of non-pharmaceutical interventions against COVID-19 and calls for a "return to normality".

# **Authors' contributions**

Anton Barchuk, Artemy Okhotin, Mikhail Cherkashin, and Oksana Stanevich conceived the study. Anton Barchuk, Artemy Okhotin, Mikhail Cherkashin, and Oksana Stanevich coordinated the study. Anton Barchuk, Artemy Okhotin, Dmitriy Skougarevskiy, and Anna Bulina drafted the first version of the manuscript. Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, and Oksana Stanevich contributed to drafting sections of the manuscript. Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya collected data for analyses. Anna Bulina, Dmitriy Skougarevskiy, and Anton Barchuk did data analyses. All authors participated in the study design, helped to draft the manuscript, contributed to the interpretation of data, and read and approved the final manuscript.

### **Declaration of interests**

Anton Barchuk reports personal fees from AstraZeneca, MSD, and Biocad outside the submitted work. Other authors have no conflict of interest to declare.

# **Acknowledgements**

We thank Alexandra Vasilieva, Alla Samoletova, and Maria Batygina (European University at St. Petersburg) for the science communication and for administrative support. We also thank Evgeny Bakin for his insightful comments and Ivan Moiseev for study support. We thank the nurses and other personnel of the MIBS. We also thank all study participants.

### References

- Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887–897.
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671–681.
- 3. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99–111.
- 4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383:2603–
- 5. Baraniuk C. Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ. 2021;372(743).
- 6. Bucci E, Andreev K, Björkman A, Calogero RA, Carafoli E, Carninci P, et al. Safety and efficacy of the Russian COVID-19 vaccine: more information needed. The Lancet. 2020;396(10256);e53.
- Bucci EM, Berkhof J, Gillibert A, Gopalakrishna G, Calogero RA, Bouter LM, et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet. 2021;397(10288):1881–1883.
- Logunov DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV. Safety and efficacy of the Russian COVID-19 vaccine: more information needed Authors' reply. The Lancet. 2020;396(10256):e54–e55.
- 9. Logunov DY, Dolzhikova IV, Shcheblyakov DV. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial Authors' reply. The Lancet. 2021;397(10288):1883–1884
- 10. Montalti M, Soldà G, Di Valerio Z, Salussolia A, Lenzi J, Forcellini M, et al. ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. EClinicalMedicine. 2021:101027.
- 11. Pagotto V, Ferloni A, Soriano MM, Diaz M, Braguinsky N, Asprea V, et al. Active surveillance of the Sputnik V vaccine in health workers. medRxiv. 2021. Available from: https://doi.org/10.1101/2021.02.03.21251071.
- 12. Evans SJW, Jewell NP. Vaccine Effectiveness Studies in the Field. New England Journal of Medicine Editorial. 2021. Available from: https://doi.org/10.1056/NEJMe2110605.
- 13. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(n1088).
- 14. Hitchings MD, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. The Lancet Regional Health Americas. 2021.
- 15. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet. 2021;397(10293):2461–2462.
- 16. Karlinsky A, Kobak D. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. eLife. 2021;10:e69336.
- 17. Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low and middle income countries, and implications for messaging.

  Nature Medicine. 2021. Available from: https://doi.org/10.1038/s41591-021-01454-y.
- 18. Barchuk A, Skougarevskiy D, Kouprianov A, Shirokov D, Dudkina O, Tursun-zade R, et al. COVID-19 pandemic in Saint Petersburg, Russia: combining surveillance and population-based serological study data in May, 2020–April, 2021. medRxiv. 2021. Available from: https://doi.org/10.1101/2021.07.31.21261428.
- 19. Morozov SP, Chemina VY, Blokhin AI, Gombolevskiy VA. Chest computed tomography for outcome prediction in laboratory-confirmed COVID-19: a retrospective analysis of 38,051 cases. Digital Diagnostics. 2020;1(1):27–36.
- 20. Williams B. The National Early Warning Score 2 (NEWS2) in patients with hypercapnic respiratory failure. Clinical Medicine. 2019;19(1):94.
- 21. WHO. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021; 2021.
- 22. Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B. 1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines. 2021;9(7):779.
- 23. Franquet T, Jeong YJ, Lam HYS, Wong HYF, Chang YC, Chung MJ, et al. Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2. The British Journal of Radiology. 2020;93(1112):20200515.
- 24. Desmet J, Biebaû C, De Wever W, Cockmartin L, Viktor V, Coolen J, et al. Performance of Low-Dose Chest CT as a Triage Tool for Suspected COVID-19 Patients. Journal of the Belgian Society of Radiology. 2021;105(1):1–8.
- 25. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology. 2020;296(1):172–180.